Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | EML4 - ALK RET C620R |
| Therapy | Pralsetinib |
| Indication/Tumor Type | medullary thyroid carcinoma |
| Response Type | predicted - resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| EML4 - ALK RET C620R | medullary thyroid carcinoma | predicted - resistant | Pralsetinib | Case Reports/Case Series | Actionable | In a clinical case study, EML4-ALK (e5:e19) was identified at the time of progression on Gavreto (pralsetinib) treatment in a patient with medullary thyroid carcinoma harboring RET C620R (PMID: 41719512). | 41719512 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (41719512) | Acquired Driver Fusions as a Mechanism of Resistance to Selective RET Inhibitors in Advanced Medullary Thyroid Carcinoma. | Full reference... |